Abstract : Objective. The minor allele of the IL4R gene single nucleotide polymorphism, rs1805010, confers impaired IL-4 signaling and has been associated with an aggressive destructive course of rheumatoid arthritis (RA). IL-4 inhibits the development of Th17 cells, a cell population recently identified to be prominent in RA patients and to associate with cartilage and bone destruction. Here, we investigated whether rs1805010 modulates Th17 cell development and, hence, subsequent clinical outcome in RA. Methods. Patients with early, active RA (n=90; DAS28 4.6 +/- 1.1) and controls (healthy subjects, [n=24], osteoarthritis patients [OA, n=15]) were genotyped. IL-17, IL-22 serum levels and Th17 cell frequencies were analyzed by ELISA and flow cytometry. Clinical and radiographic data were collected and evaluated at baseline and one year after disease onset. Results. 26% of the patients were homozygous for the major allele of rs1805010, 60% were heterozygous, and 14% were homozygous for the minor allele. RA patients homozygous for the minor allele demonstrated significantly higher clinical activity associated with the presence of erosions after one year of follow-up as compared to the other patients. The inhibitory effect of IL-4 on Th17 development in those patients was significantly less prominent. Accordingly, frequencies of Th17 cells and IL-17 and IL-22 serum levels were significantly increased. Conclusion. The data indicate that the minor allele of rs1805010 contributes to increased Th17 cell frequency, enhanced clinical activity and accelerated radiographic progression in RA by rendering CD4 T cells from RA patients insensitive to the attenuating effect of IL-4 on Th17 cell development. (c) 2014 American College of Rheumatology. |